RedShift BioAnalytics introduced its first system, the AQS³pro platform, in 2018. The AQS³pro platform performs secondary structural analysis of proteins, enabling insight into drug safety and efficacy and monitoring from development through manufacturing. The system employs the company’s proprietary Microfluidic Modulation Spectroscopy (MMS) for label-free protein characterization based on IR spectroscopy and microfluidics to enable less costly, more efficient and more flexible secondary structure analysis. A continuous flow of sample and buffer streams enhances sensitivity for characterization of protein aggregation, quantitation, stability, similarity and structure.
In January, RedShiftBio appointed Julien Bradley as CEO to lead the company through its next phase. He comes to the company from well-established analytical instrument makers Quanterix and Thermo Fisher Scientific. RedShiftBio recently completed a Series D Preferred Stock financing, raising $18 million. Investors include Waters, a $2.4 billion analytical instrument company, and private equity firm Technology Venture Partners.